PC
CPRX icon

Prairiewood Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Prairiewood Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,609
Closed -$213K – 77
2022
Q3 		$213K Sell
16,609
-241,012
-94% -$2.86M 0.18% 71
2022
Q2 		$1.81M Sell
257,621
-452
-0.2% -$3.31K 1.43% 19
2022
Q1 		$2.14M Sell
258,073
-3,330
-1% -$23.5K 1.5% 19
2021
Q4 		$1.77M Sell
261,403
-6,034
-2% -$39.7K 1.4% 20
2021
Q3 		$1.42M Buy
267,437
+10,871
+4% +$59.4K 1.16% 21
2021
Q2 		$1.48M Buy
256,566
+1,300
+0.5% +$6.71K 1.26% 20
2021
Q1 		$1.18M Buy
255,266
+41,834
+20% +$166K 1.08% 24
2020
Q4 		$713K Buy
+213,432
New +$717K 0.73% 43

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Prairiewood Capital's CPRX Position: Q4 2022 in Review

Prairiewood Capital sold out of Catalyst Pharmaceutical (CPRX) in Q4 2022, closing a stake of 16,609 shares — an estimated $213K sold.

Prairiewood Capital first reported a position in CPRX in Q4 2020 and held it in 8 quarters. The position peaked at $2.14M in Q1 2022. 257 funds tracked by Wall St. Rank hold CPRX as of Q4 2022.

  • Prairiewood Capital reported no remaining Catalyst Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Prairiewood Capital sold 16,609 Catalyst Pharmaceutical shares in Q4 2022, an estimated $213K.
  • Prairiewood Capital first reported a position in Catalyst Pharmaceutical in Q4 2020 and held it in 8 quarters.
  • Prairiewood Capital's Catalyst Pharmaceutical position peaked at $2.14M in Q1 2022.
  • 257 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2022.

Based on Prairiewood Capital's 13F filing for Q4 2022, filed 20 Jan 2023.